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Summary A 49-year-old woman complaining of anterior chest pain underwent emergent coro-
nary angiogram and thrombotic obstruction in the proximal left anterior descending artery was
discovered. Deployment of a bare metal stent recovered good coronary ﬂow and congestive
heart failure was soon relieved. However, on day 3 of hospitalization, chest radiography sud-
denly showed newly emergent bilateral pulmonary inﬁltration shadow mimicking congestive
heart failure. Chest computed tomography and clinical ﬁndings suggested bilateral alveolar
hemorrhage. The patient received dual antiplatelet therapy, aspirin 100mg/day and clopidogrel
75mg/day and continuous 15,000U/day heparin infusion, after percutaneous coronary inter-
vention. Therapies that minimize bleeding risk while maintaining an antithrombotic effect are
required for patients with acute coronary syndrome (ACS). Due to concern about the increased
risk of early stent thrombosis induced by discontinuation of antiplatelet therapy, we continued
to administer dual antiplatelet therapy. Pulmonary hemorrhage complicated with ACS without
abciximab is a rare clinical entity, and we successfully overcame this potentially life-threatening
complication with conservative
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ntroduction
urrently percutaneous coronary intervention (PCI) is widely
erformed all over the world, and multiple antiplatelet
rugs have become standard therapy for preventing throm-
otic events after PCI. However, bleeding complications
uring the treatment for acute coronary syndrome (ACS) is a
elatively frequent non-cardiac event and sometimes asso-
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Table 1 Laboratory data on admission
WBC 10610/l LDH 297U/l
RBC 3.95× 106/l ALP 655U/l
Hgb 11.7 g/dl T-Bil 0.2mg/dl
Hct 36.5% CRP 0.1mg/dl
PLT 25.3× 104/l BS 195mg/dl
BUN 26.4mg/dl TP 6.8 g/di
Cre 1.17mg/dl Alb 3.6 g/di
Na 138mequiv./l TG 52mg/dl
K 3.9mequiv./l HDL-C 39.4mg/dl
Cl 106mequiv./l LDL-C 104.0mg/dl
Amy 78 IU/l TropT Positive
CPK 217U/l PT 113%
AST 74U/l APTT 24.9 s
ALT 84U/l Fibrinogen 440mg/dl
Alb, albumin; Amy, amylase; AST, aspartate aminotransferase;
ALP, alkaline phosphatase; ALT, alanine aminotransferase; APTT,
activated partial thromboplastin time; BS, blood sugar; BUN,
blood urea nitrogen; CPK, creatine phosphokinase; Cre, serum
creatinine; CRP, c-reactive protein; Hct, hematocrit; HDL-C,
high density lipoprotein cholesterol; Hgb, hemoglobin; LDH, lac-
tate dehydrogenase; LDL-C, low density lipoprotein cholesterol;
g
i
s
t
t
t
8
w
e
t
d
h
F
t
t38
iated with a poor hospital prognosis. Although pulmonary
emorrhage can be easily misdiagnosed as congestive heart
ailure on chest radiogram, we have to investigate the
athological entity as accurately as possible to achieve a
etter outcome for these patients.
ase report
49-year-old medium-sized woman (body mass index = 21.4)
ho had been receiving medication therapy for diabetes
ellitus (DM) consulted the emergency room complaining of
udden onset anterior chest pain in the early morning. Her
nly coronary risk factor was DM. Her blood pressure was
45/92mmHg, and the pulse rate was 54/min with regu-
ar rhythm. A 12-lead electrocardiography demonstrated an
levated ST-segment in a wide range of anterior chest leads
nd ultrasound cardiography showed akinesis of broad apico-
nterior wall of left ventricle. Laboratory study showed
ypical ACS ﬁndings of acute phase (Table 1). She was
ighly suspected of having acute apico-anterior myocardial
nfarction and underwent emergent coronary angiogram.
roximal left anterior descending artery (LAD) was totally
ccluded by thrombus (Fig. 1A) and PCI was continuously
erformed. During the PCI procedure, acute pulmonary con-
estion worsened rapidly and cardiogenic shock developed
Fig. 2A). The patient was intubated and artiﬁcial ventilation
as started. Successful aspiration of red thrombus achieved
AD recanalization and demonstrated moderate LAD steno-
is (Fig. 1B, Arrow). Then, bare metal stent deployment
romptly achieved thrombolysis in myocardial infarction
rade 3 ﬂow under intra-aortic balloon pumping (IABP) sup-
ort (Fig. 1C).
The patient was admitted to the coronary care unit.
he received aspirin 200mg and clopidogrel 300mg loading
ose in the emergency room. After admission, she received
spirin 100mg/day and clopidogrel 75mg/day from the
tomach tube. Unfractionated heparin 15,000U/day was
lso continuously dripped. Medication for congestive heart
ailure effectively improved her respiratory state. Chest
adiography on day 2 of hospitalization showed remarkable
mprovement of pulmonary congestion compared with that
n admission (Fig. 2B). However, on day 3 of hospitalization
er blood oxygenation suddenly decreased and chest radio-
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igure 1 Emergent coronary angiogram showed obstruction of pr
hrombus, stenotic lesion was shown in the mid-left anterior descendi
hrombolysis in myocardial infarction grade 3 coronary ﬂow and thePLT, platelet count; PT, ptothrombin time; RBC, red blood cell
count; T-Bil, total bilirubin; TG, triglyceride; TP, total protein;
TropT, troponin T; WBC, white blood cell count.
raphy demonstrated newly emergent bilateral pulmonary
nﬁltration shadow (Fig. 2C). Chest computed tomography
howed a ground-glass appearance with partial consolida-
ion at the bilateral posterior lung ﬁeld (Fig. 3). At the same
ime, some fresh blood was aspirated through the intubated
ube, and her hemoglobin decreased from 10.5mg/dl to
.4mg/dl. Findings suggested that her clinical pathology
as derived from pulmonary hemorrhage rather than wors-
ning of congestive heart failure. The activated coagulation
ime was measured as 170 s and platelet number was
ecreased to 58,000/l. Therefore, we ceased continuous
eparin infusion and discontinued IABP mechanical sup-
ort. We then tried conservative treatment for pulmonary
emorrhage with continuous infusion of carbazochrome
nd tranexamic acid, and transfusion with 2 units of red
ell concentrates mannitol adenine phosphate. Considering
he patient’s cardiac state, we continued dual antiplatelet
oximal left anterior descending artery (A). After aspiration of
ng artery (B, arrow). Deployment of bare metal stent recovered
procedure was successfully ﬁnished (C).
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Figure 2 Transition of images on chest radiogram. Severe pulmonary congestion was seen on coronary care unit admission (A).
Pulmonary congestion quickly recovered on day 2 of hospitalization (B). Bilateral inﬁltration shadow appeared on day 3 (C).
l gro
agesFigure 3 Chest computed tomography demonstrated bilatera
at the lower posterior lung ﬁeld on day 3 of hospitalization. Im
the carina (B), and at the level of mid-left ventricle (C).therapy. Because of the persistence of a low PaO2/FiO2 (P/F
ratio) score, we started sivelestat infusion and her respi-
ratory state dramatically improved. She was extubated on
day 8 of hospitalization (Fig. 4). Thereafter, she progressed
w
c
m
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Figure 4 Changes in the medical treatment and clinical course du
IABP, intra-aortic balloon pumping; MAP, mannitol adenine phosphatund-glass appearance with partial consolidation predominantly
show the horizontal section just above the carina (A), belowell without relapse of either pulmonary hemorrhage or
ongestive heart failure. Cardiac rehabilitation after acute
yocardial infarction gradually progressed, and she was
nally discharged on day 30 of hospitalization.
ring the early stage of hospitalization. CRP, C-reactive protein;
e; P/F ratio, PaO2/FiO2 ratio; WBC, white blood cells.
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iscussion
n most cases of PCI in the modern era, stent deployment
s a fundamental and very useful strategy. However, once
tent thrombosis occurs, catastrophic results often follow.
s reported by Schomig et al. [1] and Leon et al. [2], potent
ntiplatelet therapy is very useful for preventing stent
hrombosis. Dual antiplatelet therapy has been reported to
educe the incidence of stent thrombosis to less than 1%.
urrently dual antiplatelet therapy is a common strategy
or interventional cardiologists after stent deployment, but
e must remember that hemorrhagic complications caused
y dual antiplatelet therapy occur as frequently as stent
hrombosis.
Also in cases of ACS, a strategy of clopidogrel pre-
reatment followed by long-term therapy is reported to
e beneﬁcial in reducing major cardiovascular events [3].
hat study also reported that there was less need for gly-
oprotein IIb/IIIa inhibitor in the clopidogrel group and
here was no increase in major or life-threatening bleed-
ng with clopidogrel use. However, when PCI is performed,
e must always consider the risk of hemorrhagic compli-
ation. Major bleeding is a relatively frequent non-cardiac
omplication of contemporary therapy for ACS and it is asso-
iated with a poor hospital prognosis. Advanced age, female
ex, history of bleeding, and renal insufﬁciency were inde-
endently associated with a higher risk of bleeding [4]. The
USTO (Global Use of Strategies To Open Occluded Coro-
ary Arteries) bleeding classiﬁcation identiﬁes patients who
re at risk for short- and long-term adverse events [5].
he reason for the increased occurrence of cardiovascu-
ar events related to bleeding complication is that these
atients show common risk factors such as advanced age
r renal insufﬁciency as indicated above. Furthermore, to
ope with those bleeding complications, we sometimes have
o discontinue antiplatelet or anticoagulant drugs, which
onsequently lead to more frequent thrombotic events.
herapies that minimize bleeding risk while maintaining an
nticoagulant effect may improve the outcomes of patients
ith ACS.
Bleeding problems from the gastrointestinal and gen-
tourinary tract or arterial access are easily recognized.
owever, wemust carefully monitor other possible but infre-
uent hemorrhagic complications. Pulmonary hemorrhage
ppears as a bilateral alveolar inﬁltration shadow on chest
adiography and can be easily mistaken for acute pulmonary
dema in the context of ACS [6]. When the inﬁltrates do
ot resolve with administration of drugs for congestive heart
ailure, cardiologists must be aware of the possibility of pul-
onary hemorrhage because early treatment can increase
he probability of patient survival.
Diffuse pulmonary hemorrhage is a rare event, which has
ostly been reported in patients receiving glycogen IIb/IIIa
nhibitors in combination with other antiplatelet drugs,
uch as aspirin, ticlopidine, and clopidogrel. Kalra et al.
eported that severe pulmonary hemorrhage was identiﬁed
n 0.27% patients who received abciximab, while there were
o cases of pulmonary hemorrhage among 5412 patients
ho underwent coronary procedures without abciximab
nfusion [7].
Clopidogrel use related to alveolar hemorrhage without
lycogen IIb/IIIa inhibitors has been infrequently reportedR. Ishida et al.
o date. In the ﬁrst report of this type of pathology, alveolar
emorrhage was controlled by ceasing clopidogrel use [8].
n the other case, the patient developed severe pulmonary
emorrhage and could not be resuscitated [9].
We successfully used the elastase inhibitor sivelestat that
s usually applied for the treatment of acute lung injury
ALI). Although our patient did not strictly correspond to the
riteria of ALI [10], she showed lower P/F ratio which is often
pplied for an index of respiratory dysfunction. From that
oint of view, we hoped the effect of this drug to improve
er respiratory state.
We presented a case of pulmonary hemorrhage com-
licated with ACS. Multifactorial causes such as dual
ntiplatelet therapy, heparin infusion, thrombocytopenia,
ncreased alveolar pressure induced by mechanical venti-
ation, and assumed pulmonary hypertension due to left
entricular dysfunction, were thought to be involved in
he occurrence of pulmonary hemorrhage in our patient.
hrombocytopenia may be related to the pathophysiology
f heparin-induced thrombocytopenia (HIT). However, no
ore information is available because further examination
bout HIT was not performed. Because our patient overcame
er hemorrhagic complication without stopping antiplatelet
se, strictly speaking, we cannot determine the direct cor-
elation between antiplatelet therapy and the hemorrhagic
vent. However, there is no doubt that the use of multi-
le antiplatelet and anticoagulant drugs is involved in the
ncreased risk of hemorrhagic events. Our patient is a case of
elatively broader anterior myocardial infarction with lower
ardiac function, which indicated that recurrent infarction
aused by early stent thrombosis is quite capable of being
atal. Deciding to stop antiplatelet medicines in such a clin-
cal setting could be fatal. Therefore, we continued dual
ntiplatelet therapy and were still able to achieve a bet-
er outcome. Making a quick and accurate diagnosis of the
linical pathology is of course important, and moreover, we
ave to fully consider the patient’s background and current
ondition to determine an appropriate treatment policy.
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